Screener
LB Pharmaceuticals Inc LBRX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by LB Pharmaceuticals Inc in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219607
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $14,645 | $3,421 |
| General and administrative | 7,459 | 3,008 |
| Total operating loss | (22,104) | (6,429) |
| Non-operating income | ||
| Interest income | 2,850 | 236 |
| Realized gain on sale of marketable securities, net | — | 119 |
| Gain on change in fair value of derivative instruments | 200 | 768 |
Item 1. Financial Statements
FAQ
- What is LB Pharmaceuticals Inc's total operating expenses?
- LB Pharmaceuticals Inc (LBRX) reported total operating expenses of $22.1M in Q1 2026.
- How has LB Pharmaceuticals Inc's total operating expenses changed year-over-year?
- LB Pharmaceuticals Inc's total operating expenses increased by 243.8% year-over-year, from $6.43M to $22.1M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about LB Pharmaceuticals Inc's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude